Saba Capital reports 355,835 BCV shares (6.07%) in Schedule 13D/A
Saba Capital Management filed Amendment No. 3 to Schedule 13D on Bancroft Fund Ltd. (BCV), reporting beneficial ownership of 355,835 common shares, representing 6.07% of the class.
Rhea-AI Filing Summary
Saba Capital Management filed Amendment No. 3 to Schedule 13D on Bancroft Fund Ltd. (BCV), reporting beneficial ownership of 355,835 common shares, representing 6.07% of the class. The percentage is based on 5,862,058 shares outstanding as of 3/31/25.
Saba and its affiliates report shared voting and dispositive power over 355,835 shares and no sole power. The filing states an aggregate purchase consideration of approximately $6,366,769. The date of the event requiring the filing is 10/29/2025, and the amendment updates Items 3, 5, and 7. Recent transactions within sixty days are listed in Schedule A.
Positive
- None.
Negative
- None.
Insights
13D/A shows a 6.07% BCV stake with shared control.
Saba Capital discloses 355,835 BCV shares, equal to 6.07% of the fund’s common shares, calculated against 5,862,058 outstanding as of 3/31/25. The group reports shared voting and dispositive power over the entire position and no sole power, indicating coordinated control among reporting persons.
Purchase consideration totals $6,366,769. The amendment date of event is 10/29/2025 and it updates Items 3, 5, and 7, with trade details referenced in Schedule A. Actual effects depend on holder actions disclosed in future materials.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Saba Capital disclose about BCV in this Schedule 13D/A?
What percentage of BCV does Saba Capital’s stake represent?
What voting and dispositive powers are reported?
What date triggered this amended filing and what items were updated?
Who are the reporting persons in this 13D/A for BCV?
AI-generated analysis. How Rhea-AI works. Not financial advice.